Search clinical trials for: non-squamous NSCLC

Total 3597 results

Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (Serpentine)

Melanoma | Renal Cell Carcinoma | Breast Cancer | NSCLC | Urinary Bladder Cancer | Squamous Cell Carcinoma of Head and Neck | Small Cell Carcinoma

Italy
LianBio LLC

Recruiting

Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Advanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung Cancer

China
The Netherlands Cancer Institute
Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaborators

Not yet recruiting

Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy (UPLAN-I)

Feasibility | Surgery | Safety | Chemoradiotherapy | Locally Advanced Non-Small Cell Lung Cancer | Cavitation Lung
Washington University School of Medicine
Polaris Group

Recruiting

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Small Cell Lung Carcinoma | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small-cell Lung Cancer

United States
Sichuan University

Recruiting

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

NSCLC | PD-1 Inhibitor | Stereotactic Body Radiotherapy | Low Dose Radiotherapy

China
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Korea, Republic of, Japan, Spain, Belgium, China
Beijing Tsinghua Chang Gung Hospital

Recruiting

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

NSCLC, Stage III

China
Tongji Hospital

Recruiting

Exercise Prehabilitation for Patients With NSCLC Before Surgery

Surgery | Non Small Cell Lung Cancer | Cardiorespiratory Fitness | Prehabilitation

China
Mirati Therapeutics Inc.

Recruiting

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (202200050434)

Metastatic Lung Cancer | Advanced NSCLC

United States, Spain, France, Hungary, Italy, Greece, Poland, Brazil, Chile, Georgia, Malaysia, Serbia, Switzerland, Thailand
Merck Sharp & Dohme LLC
Gilead Sciences

Recruiting

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Carcinoma, Non-Small-Cell Lung

China, Poland, Latvia, United States, Taiwan, Australia, Turkey, Germany, Israel, Korea, Republic of, Estonia, Romania, Chile, Italy, Brazil, Greece, Philippines, Canada, Japan, Malaysia, United Kingdom, Lithuania, Thailand, Peru
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom, Mexico
Xuhua Duan

Recruiting

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

NSCLC

China
ImmVira Pharma Co. Ltd

Recruiting

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Sarcoma | Breast Cancer | NSCLC | Advanced Solid Tumor | HNSCC | Esophagus Cancer | Non-melanoma Skin Cancer

China
Centre Hospitalier Universitaire de Liege

Recruiting

PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC). (PROTEON)

Non-small Cell Lung Cancer

Belgium
ETOP IBCSG Partners Foundation
Janssen Pharmaceuticals

Recruiting

AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung)

Non Small Cell Lung Cancer

Spain, France, Switzerland, United Kingdom, Singapore, Italy, Netherlands
Bristol-Myers Squibb

Recruiting

A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung Cancer (AURORA)

Carcinoma, Non-Small-Cell Lung

Greece
Peking Union Medical College Hospital
Merck Sharp & Dohme LLC; BeyondSpring Pharmaceuticals Inc.

Recruiting

Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) (KeyPemls-004)

Non Small Cell Lung Cancer Metastatic

China
Second Xiangya Hospital of Central South University
The First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central... and other collaborators

Recruiting

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) (PRECISE)

Lung Cancer, Non-small Cell | Circulating Tumor DNA | EGFR Gene Mutation | EGFR-TKI Resistant Mutation | Primary Resistance

China
Universita di Verona

Not yet recruiting

Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR)

HIV | HBV | Long COVID | NSCLC Stage IV | HCV

Italy
Luzerner Kantonsspital

Recruiting

Role of Intrapulmonary Lymph Nodes in Patients With NSCLC and Visceral Pleural Invasion

Lung Cancer | Lymph Node Metastasis

Switzerland
Icahn School of Medicine at Mount Sinai

Recruiting

Pembrolizumab for Advanced NSCLC and PS 2-3

Non-Small Cell Lung Cancer (NSCLC)

United States
Merus N.V.

Recruiting

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Metastatic Castration-resistant Prostate Cancer | NSCLC Harboring NRG1 Fusion

United States
University of Arizona
Biotechnology High Performance Computing Software Applications Institute; U...

Recruiting

Caffeine Optimization Versus Standard Caffeine Dosage (2B-2) (2B-2)

Sleep Deprivation | Caffeine

United States
Immuneering Corporation

Recruiting

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Pancreatic Adenocarcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC) | Malignant Melanoma (Cutaneous)

United States
Li Zhang
Hubei Cancer Hospital

Not yet recruiting

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Stage IV Non-small Cell Lung Cancer

China
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Melanoma | Cervical Cancer | HCC | Gastric Cancer | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Locally Advanced or Metastatic Solid Tumors | TNBC | Clear Cell RCC

Korea, Republic of, Netherlands, Spain, United States, Australia, Canada, Belgium
Wuhan University

Not yet recruiting

SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases

NSCLC
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Carcinoma, Non-Small-Cell Lung

United States, Australia, Belgium, Chile, France, Spain
Tianjin Chest Hospital

Recruiting

Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

NSCLC With COPD

China
Mirati Therapeutics Inc.

Recruiting

A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Solid Tumor | Non Small Cell Lung Cancer | Advanced Solid Tumor | Colo-rectal Cancer

United States, Puerto Rico
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL845 in Adults With Solid Tumors

Melanoma | Colorectal Cancer | Non-small Cell Lung Cancer

United States
Seagen Inc.

Recruiting

A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Colorectal Neoplasms | Pancreatic Neoplasms | Mesothelioma | Non-small Cell Lung Cancer | Cutaneous Melanoma

United States, Canada, Switzerland, France, Germany, United Kingdom
Fondazione Ricerca Traslazionale

Recruiting

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Non-small-cell Lung Cancer Patients

Italy
Intima Bioscience, Inc.

Not yet recruiting

CISH Inactivated TILs in the Treatment of NSCLC (CheckCell-2)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Large Cell Lung Cancer

United States
Institut universitaire de cardiologie et de pneumologie...

Not yet recruiting

Optimizing Endobronchial Ultrasound Sampling for Molecular Markers for NSCLC (OPTIMAL)

Lung Cancer | Non Small Cell Lung Cancer | Circulating Tumor Cell
Peking Union Medical College Hospital
Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Recruiting

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) (WU-KONG15)

Non Small Cell Lung Cancer

China
Regeneron Pharmaceuticals
BioNTech SE

Recruiting

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Advanced Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, Georgia, Taiwan, Germany, Turkey
Radboud University Medical Center
Johnson & Johnson; Philips Healthcare

Recruiting

Injection of 99mTc-nanocolloid and ICG to Identify, Retrieve and Qualify TDLN in Early-stage NSCLC (INITIATE)

Early-stage Lung Cancer

Netherlands
Qilu Pharmaceutical Co., Ltd.

Recruiting

To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation

Non-small Cell Lung Cancer

China
RedCloud Bio
R&G Pharma Studies Co.,Ltd.

Recruiting

H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

China
Duke University
Regeneron Pharmaceuticals

Recruiting

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Non-small Cell Lung Cancer (NSCLC)

United States
Hunan Province Tumor Hospital

Recruiting

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC (PACIFIC15)

Non-small Cell Lung Cancer

China
Fondazione IRCCS Istituto Nazionale dei Tumori,...
University of Campania "Luigi Vanvitelli"; Istituti Ospitalieri di Cremona; Istituto... and other collaborators

Recruiting

APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Cancer | NSCLC | Lung Cancer | Adenocarcinoma of Lung | Squamous Cell Lung Cancer

Italy
AstraZeneca

Recruiting

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

Non-small Cell Lung Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer (NSCLC)

NSCLC
Chongqing University Cancer Hospital
Army Specialty Medical Center; The Second Affilicated Hospital of Chongqing...

Recruiting

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Non-small Cell Lung Cancer | EGFR G719X | EGFR L861Q | EGFR S768I

China
Odense University Hospital

Not yet recruiting

Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC (HERAN2)

Frailty | Non-small Cell Lung Cancer Stage III | Radiotherapy Side Effect
Novartis Pharmaceuticals

Recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...

Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States
Monte Rosa Therapeutics, Inc

Recruiting

Study of Oral MRT-2359 in Selected Cancer Patients

NSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast Cancer

United States, Canada

Search clinical trials for: non-squamous NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations